Woodcock’s Passion Project: CDER Chief Shifts Duties To Lead Quality Office
Deputies are taking on some of Woodcock’s usual responsibilities to allow the center director more time to oversee launch of new Office of Pharmaceutical Quality.
You may also be interested in...
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.
Implementer of many drug review changes will leave in January after nearly 32 years of public service.
Center for Drug Evaluation and Research's long-time director of oncology/hematology products office will continue as signatory on drug reviews even after new Cancer Moonshot-driven structure takes effect.